c-Met inhibitor approved in China for lung cancer
The Chinese National Medical Products Administration (NMPA) has granted conditional approval to Apollomics’ partner Avistone Biotechnology to commercialise vebreltinib (APL-101) in China for MET exon 14 skipping non-small cell lung cancer (NSCLC). “The NMPA approval of vebreltinib is an important milestone toward providing a new treatment… Read More